Related Experiment Video
Updated: Dec 7, 2025
05:26
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
Published on: September 16, 2022
4.4K
[Liquid biopsy-a possible key player in immuno-oncology].
M Wallesch1, M Wirth1, B Wollenberg2
1Klinik und Poliklinik für Hals‑, Nasen- und Ohren Heilkunde des Klinikums rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland.
HNO
|September 30, 2020
Summary
Liquid biopsy offers a promising minimally invasive approach for head and neck cancer treatment monitoring. Further research is needed to standardize these methods for clinical application.
Area of Science:
- Oncology
- Molecular Diagnostics
Background:
- Immune checkpoint inhibitors (ICI) are transforming head and neck cancer treatment.
- Predictive and prognostic markers are crucial, especially for advanced and HPV-negative disease.
- Current markers are insufficient for guiding therapy in complex cases.
Purpose of the Study:
- To review the current literature on liquid biopsy applications in head and neck cancer.
- To explore the potential of liquid biopsy as a predictive and prognostic tool.
- To assess the role of liquid biopsy in personalizing head and neck cancer treatment.
Main Methods:
- Selective literature review of PubMed.
- Keywords included: cytodiagnostics, circulating tumor cells, liquid biopsy, cfDNA, exosomes, head and neck cancer, immune checkpoint inhibitor therapy.
- Articles published until March 2020 were included and selected for relevance.
Main Results:
- Liquid biopsy analyzes circulating tumor cells or tumor genetic material in body fluids.
- This minimally invasive analysis supports therapeutic decisions.
- Liquid biopsy enables a personalized approach to head and neck cancer treatment.
Conclusions:
- Liquid biopsy shows potential for head and neck cancer management.
- Standardization of isolation and analysis methods is required.
- Long-term clinical data are necessary before routine implementation.
